ESMO Highlights

The Impact of mFOLFOX Chemotherapy in Conjunction with Active Symptom Control on Patient QOL: The ABC-06 Trial

Web Exclusives — December 7, 2022

Preliminary analyses of patient quality-of-life data from the ABC-06 clinical trial suggest a potentially positive impact of L-folinic acid plus oxaliplatin plus 5-fluorouracil when used in conjunction with active symptom control.

Derazantinib Shows Clinical Efficacy in the Treatment of iCCA in Patients with Genetically Aberrant FGFR2

ESMO Highlights

Web Exclusives — December 7, 2022

Data from the FIDES-01 clinical trial showed encouraging results for derazantinib as a second-line treatment for patients with intrahepatic cholangiocarcinoma with FGFR2 fusions, mutations, or amplification.

Real-World Evidence for Liquid Biopsy to Identify Molecular Alterations

ESMO Highlights

Web Exclusives — December 7, 2022

Real-world evidence supports a role for liquid biopsy in identifying molecular alterations, offering personalized treatment options.

FGFR Inhibitor RLY-4008 Shows Promise in Treating Metastatic CCA

ESMO Highlights

Web Exclusives — December 7, 2022

Early data from the ReFocus trial indicated that the highly selective FGFR2 inhibitor RLY-4008 may be an effective new treatment for cholangiocarcinoma in patients with FGFR2 fusions or rearrangements.

Nanoliposomal Irinotecan Combination Therapy Falls Short in Metastatic BTC

ESMO Highlights

Web Exclusives — November 22, 2022

The NALIRICC study compared the efficacy of nanoliposomal irinotecan plus 5-fluorouracil (5-FU) plus leucovorin (LV) with 5-FU plus LV on progression-free and overall survival in patients with biliary tract cancer.

Tislelizumab as Part of a Conversion Therapy Regimen for Potentially Resectable Biliary Tract Cancers

ESMO Highlights

Web Exclusives — November 22, 2022

A phase 2 study found that the combination of tislelizumab, lenvatinib, and gemcitabine/oxaliplatin showed promise as a conversion therapy for patients with potentially resectable locally advanced biliary tract cancer, making curative surgery a possibility for some patients.

Additional 6-Month Follow-up from the TOPAZ-1 Study Comparing Durvalumab with Placebo plus Gem/Cis in Patients with Advanced BTC

ESMO Highlights

Web Exclusives — November 15, 2022

Updated overall survival (OS) and safety data from the TOPAZ-1 study revealed improved median OS for the full patient population as well as subgroup analyses and an adverse event profile consistent with previously reported data.

ESMO Highlights

Web Exclusives — November 15, 2022

Analysis of the safety population in the TOPAZ-1 trial in patients with biliary tract cancer revealed that immune-related adverse events were more common in the durvalumab arm, had a variable time to onset, and were associated with improved overall survival.

CCA Summit Live from ESMO 2022

By Juan W. Valle, MB ChB, MSc, FRCP

ESMO Highlights

Videos — October 4, 2022

On September 21, 2022, I presented an overview of key abstracts on biliary tract cancer (BTC) presented at the 2022 annual meeting of the European Society for Medical Oncology. In addition, I provided my perspective on the impact of the data on the management of patients with BTC.

Key Abstracts Presented at the European Society for Medical Oncology (ESMO) 2021 Annual Meeting

By Richard Kim, MD

ESMO Highlights

Videos — September 29, 2021

Richard Kim, MD, from the Moffitt Cancer Center, University of South Florida College of Medicine, provides expert commentary on key abstracts and posters presented at the 2021 annual meeting of the European Society for Medical Oncology. Dr Kim will highlight new data from 11 presentations on interventional modalities for patients with cholangiocarcinoma.

ESMO Highlights

Subscribe Today!

I'd like to receive:

Stay In The Know

ESMO Highlights

Page 1 of 2

Subscribe Today!

I'd like to receive:

Stay In The Know